PFAS linkage
- PFAS chemicals are studied for endocrine, immune, and reproductive effects that may be relevant to ovarian cancer pathways.
- The evidence for ovarian cancer is developing, so case evaluation relies on strong exposure documentation and clear medical records.
- Potential exposure sources include contaminated water, industrial releases, military or airport sites, and AFFF firefighting foam.
Ovarian cancer symptoms
- Persistent bloating or abdominal swelling
- Pelvic or abdominal pain
- Feeling full quickly or difficulty eating
- Urinary urgency or frequency
- Unexplained weight change, fatigue, constipation, or menstrual changes
Diagnosis and medical records
- Pelvic exam and transvaginal ultrasound
- Blood tests such as CA-125 and other tumor markers when appropriate
- CT, MRI, or PET imaging to evaluate spread
- Surgical pathology to confirm tumor type and stage
Treatment options
- Surgery to remove visible disease and stage the cancer
- Chemotherapy, often platinum-based, before or after surgery
- Targeted therapy such as PARP inhibitors or anti-angiogenic therapy in selected patients
- Maintenance therapy, clinical trials, or palliative treatment for recurrent disease
What patients should gather for intake
- Gather surgical pathology, staging reports, CA-125 trends, chemotherapy records, and genetic testing results.
- Document possible exposure before diagnosis, including water sources and workplaces.
- Include family history, BRCA or other genetic testing, and recurrence history if known.
Medical and attorney advertising notice. This page is for general information only and is not medical advice. Talk with your treating clinician about diagnosis and treatment. Submitting an intake form does not create an attorney-client relationship, and cases may be referred to qualified national PFAS co-counsel.